LT1854477T - Peptidai, slopinantys plazmos kalikreiną, skirti naudoti oftalmologinių sutrikimų gydymui - Google Patents

Peptidai, slopinantys plazmos kalikreiną, skirti naudoti oftalmologinių sutrikimų gydymui

Info

Publication number
LT1854477T
LT1854477T LTEP07005182.6T LT07005182T LT1854477T LT 1854477 T LT1854477 T LT 1854477T LT 07005182 T LT07005182 T LT 07005182T LT 1854477 T LT1854477 T LT 1854477T
Authority
LT
Lithuania
Prior art keywords
treatment
plasma kallikrein
ophthalmic disorders
inhibiting plasma
peptides inhibiting
Prior art date
Application number
LTEP07005182.6T
Other languages
English (en)
Inventor
Pierre Belichard
Original Assignee
Dyax Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp. filed Critical Dyax Corp.
Publication of LT1854477T publication Critical patent/LT1854477T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
LTEP07005182.6T 2006-03-16 2007-03-13 Peptidai, slopinantys plazmos kalikreiną, skirti naudoti oftalmologinių sutrikimų gydymui LT1854477T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06360008 2006-03-16
EP06291516 2006-09-26

Publications (1)

Publication Number Publication Date
LT1854477T true LT1854477T (lt) 2016-12-12

Family

ID=38292592

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP11152204.1T LT2374472T (lt) 2006-03-16 2007-03-13 Kompozicijos ir būdai oftalmologinių sutrikimų gydymui
LTEP07005182.6T LT1854477T (lt) 2006-03-16 2007-03-13 Peptidai, slopinantys plazmos kalikreiną, skirti naudoti oftalmologinių sutrikimų gydymui

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP11152204.1T LT2374472T (lt) 2006-03-16 2007-03-13 Kompozicijos ir būdai oftalmologinių sutrikimų gydymui

Country Status (12)

Country Link
US (3) US20070270344A1 (lt)
JP (2) JP5337493B2 (lt)
AU (1) AU2007224643B2 (lt)
CA (1) CA2646285C (lt)
DK (1) DK1854477T3 (lt)
ES (2) ES2682646T3 (lt)
HU (2) HUE031701T2 (lt)
LT (2) LT2374472T (lt)
PL (1) PL1854477T3 (lt)
PT (2) PT2374472T (lt)
SI (1) SI2374472T1 (lt)
WO (1) WO2007104541A2 (lt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
DK1941867T3 (da) 2002-06-07 2012-01-02 Dyax Corp Polypeptid med modificeret Kunitz domæne
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2005021557A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006091459A2 (en) * 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
JP2009522302A (ja) 2005-12-30 2009-06-11 ダイアックス コーポレーション マトリックスメタロプロテイナーゼ結合タンパク質
LT2374472T (lt) * 2006-03-16 2018-09-25 Dyax Corp. Kompozicijos ir būdai oftalmologinių sutrikimų gydymui
WO2008091692A2 (en) * 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Methods of diagnosing, treating, and preventing increased vascular permeability
WO2009079585A2 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
US20110262396A1 (en) * 2008-10-22 2011-10-27 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
WO2010080833A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CA3168591A1 (en) 2010-01-06 2011-07-14 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
KR20150132473A (ko) 2013-03-15 2015-11-25 다이액스 코포레이션 항-혈장 칼리크레인 항체
WO2015063465A2 (en) 2013-10-28 2015-05-07 Bicycle Therapeutics Limited Novel polypeptides
PT3096798T (pt) 2014-01-21 2021-02-25 Dyax Corp Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário
IL295414A (en) * 2014-03-27 2022-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema as a result of diabetes
WO2017087018A1 (en) * 2015-11-18 2017-05-26 University Of Louisville Research Foundation, Inc. Automated methods for the objective quantification of retinal characteristics by retinal region and diagnosis of retinal pathology
RU2622031C1 (ru) * 2015-12-07 2017-06-08 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения РФ Способ комбинированного лечения макулярного отека сетчатки
NZ744233A (en) 2015-12-11 2023-11-24 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
GB201522441D0 (en) * 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
WO2020210368A1 (en) * 2019-04-08 2020-10-15 Biocryst Pharmaceuticals, Inc. Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
LT6899B (lt) * 2020-08-27 2022-04-11 Valstybinis mokslinių tyrimų institutas Fizinių ir technologijos mokslų centras Vario paviršiaus cheminio nikeliavimo būdas, nenaudojant aktyvavimo paladžiu
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
US5217951A (en) * 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
PT739355E (pt) * 1994-01-11 2005-01-31 Dyax Corp Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
PT1489097E (pt) * 1994-01-11 2012-01-04 Dyax Corp Inibidores de plasmina humana derivados de domínios kunitz e ácidos nucleicos codificando os mesmos
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
DE10060653A1 (de) * 2000-12-06 2002-06-20 Epcos Ag Elektrischer Doppelschicht-Kondensator
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
WO2003066085A1 (en) 2002-02-07 2003-08-14 Delta Biotechnology Limited Albumin-fused anti-angiogenesis peptides
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK1941867T3 (da) * 2002-06-07 2012-01-02 Dyax Corp Polypeptid med modificeret Kunitz domæne
SI2386310T1 (sl) * 2002-08-28 2019-03-29 Dyax Corp. Metode za ohranjanje organov in tkiv
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
AU2004268144A1 (en) * 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
WO2005021557A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
US7276480B1 (en) * 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
JP2009529542A (ja) * 2006-03-10 2009-08-20 ダイアックス コーポレーション エカランチドに関する配合物
LT2374472T (lt) 2006-03-16 2018-09-25 Dyax Corp. Kompozicijos ir būdai oftalmologinių sutrikimų gydymui
US8467792B2 (en) * 2006-06-27 2013-06-18 Qualcomm Incorporated Method and apparatus for maintaining call continuity in wireless communication
JP2010536870A (ja) * 2007-08-21 2010-12-02 ジェンザイム・コーポレーション カリクレイン阻害剤を用いた治療
EP2195011A4 (en) * 2007-08-23 2010-12-01 Genzyme Corp TREATMENT WITH CALLICINE INHIBITORS
US20110262396A1 (en) 2008-10-22 2011-10-27 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders

Also Published As

Publication number Publication date
LT2374472T (lt) 2018-09-25
ES2682646T3 (es) 2018-09-21
HUE039108T2 (hu) 2018-12-28
US20070270344A1 (en) 2007-11-22
PT2374472T (pt) 2018-08-08
JP2012211194A (ja) 2012-11-01
HUE031701T2 (en) 2017-07-28
JP2009529553A (ja) 2009-08-20
WO2007104541A3 (en) 2008-06-26
US20150368359A1 (en) 2015-12-24
AU2007224643B2 (en) 2012-10-11
SI2374472T1 (sl) 2018-11-30
AU2007224643A1 (en) 2007-09-20
JP5337493B2 (ja) 2013-11-06
CA2646285A1 (en) 2007-09-20
CA2646285C (en) 2020-04-28
WO2007104541A2 (en) 2007-09-20
DK1854477T3 (en) 2016-11-28
PL1854477T3 (pl) 2017-02-28
US9107928B2 (en) 2015-08-18
PT1854477T (pt) 2016-11-10
ES2601554T3 (es) 2017-02-15
US20100273721A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
PL1854477T3 (pl) Peptydy hamujące kalikreinę osoczową do zastosowania w leczeniu zaburzeń okulistycznych
IL191283A (en) Compositions for treating eye irregularities
ZA200800464B (en) Peptides for use in the treatment of obesity
IL193747A0 (en) New therapeutic combinations for the treatment of depression
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
GB0602178D0 (en) Therapeutic treatment
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
ZA200901523B (en) Use of extracts for the treatment of viral disorders
GB0608655D0 (en) Therapeutic Treatment
IL196667A (en) Use of peptides to prepare a drug to treat inflammation
GB0523961D0 (en) The treatment of ophthalmic diseases
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
EP2225196A4 (en) CYSTONE PROTEASE INHIBITOR FOR THE TREATMENT OF PARASITIC DISEASES
GB0714447D0 (en) Cannabidiol for use in the treatment of neurodegenerative conditions
GB0610909D0 (en) Therapeutic treatment
ZA200902453B (en) PAI-1 binding modulators for the treatment of ocular disorders
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
SI1854477T1 (sl) Peptidi, ki inhibirajo plazma kalikrein za uporabo pri zdravljenju očesnih motenj
EP2023894A4 (en) FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE
SI1714647T1 (sl) Uporaba agomelatina pri izdelavi zdravila za zdravljenje bipolarnih motenj
GB0523964D0 (en) The treatment of ophthalmic diseases
IL193414A0 (en) Meridamycin analogues for the treatment ofneurodegenererative disorders
GB0602857D0 (en) The treatment of sialorrhoea
GB0610376D0 (en) Therapeutic treatment
HK1125634A1 (en) Pharmaceutical for use in the treatment of ureterolithiasis